SRPT
Sarepta Therapeutics, Inc.
Key Financials
Revenue
$2.2B
↑ 396.3%
Gross Profit
$-29101000
↓ 113.3%
Operating Income
$-699781000
↓ 420.9%
Net Income
$-713410000
↓ 73.1%
EPS (Diluted)
$-7.13
↓ 81.4%
Total Assets
$3.3B
↓ 15.5%
Shareholders' Equity
$1.1B
↓ 25.3%
Total Liabilities
$2.2B
↓ 9.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 13F-HR | 5/13/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| SCHEDULE 13G | 4/30/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
| ARS | 4/24/2026 | View on SEC |
| DEFA14A | 4/24/2026 | View on SEC |
| DEF 14A | 4/24/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SRPT |
| Company Name | Sarepta Therapeutics, Inc. |
| CIK | 873303 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-274-4000 |